XOMA Royalty Corporation: Customer Relationships and What They Mean for Investors

XOMA Royalty Corporation operates as a biopharma royalty aggregator: it acquires licenses, milestone and royalty streams, and saleable future-revenue interests from biotech originators and partners, and monetizes those positions through milestone receipts and ongoing royalties across geographies. Revenue is earned chiefly as licensing income, purchased receivables proceeds, milestones and royalties, concentrated across the U.S., Europe and Asia‑Pacific. For a concise view of XOMA’s customer linkages and the investment implications, visit https://nullexposure.com/.

The operating model in plain terms: contracting posture, concentration and maturity

XOMA’s commercial posture is asset‑centric and contractual: the company functions primarily as a licensor and royalty investor rather than an operator of late‑stage therapeutics. The company’s revenue mix — upfronts, milestone payments and percentage royalties — signals a contracting model that is structurally predictable when assets commercialize but uneven in timing and binary on development success. Geographical exposure is global with material activity in North America, EMEA and APAC, supporting diversified revenue sources but also dependence on multinational commercialization partners.

• Contracting posture: XOMA acts as a licensor and buyer of future revenue streams — contracts are long‑dated, non‑recurring and performance‑contingent.
• Concentration: Material upside is concentrated in a set of late‑stage or commercial assets (e.g., mezagitamab, VABYSMO, OJEMDA), making a handful of counterparties strategically important.
• Criticality: For XOMA, counterparties that commercialize products are mission‑critical because XOMA only realizes value as partners hit milestones or deliver sales.
• Maturity: The portfolio mixes mature commercial royalties with development‑stage CVRs and milestone exposures, creating a hybrid cash‑flow profile.

These operating model signals are consistent with XOMA’s own disclosures that its segment income includes revenues from licenses, royalties and sale of future revenue streams and that its income is primarily derived from the U.S., Europe and Asia Pacific.

Constraints and company‑level signals

• Contract type — licensing: XOMA recognizes revenue from licenses and sales of future revenue streams, confirming a licensing‑and‑royalty business model rather than a product sales model (company filings).
• Geography: The business is geographically diversified across NA, EMEA and APAC, which reduces single‑market exposure but links payouts to international product approvals and partner commercial execution.
• Relationship role — licensor: XOMA consistently occupies the licensor/investor role in arrangements, receiving royalties and milestone streams rather than carrying development or commercialization obligations.

Catalog of every customer relationship cited in public sources

Below are the relationships extracted from XOMA filings and market coverage. Each entry is a one‑to‑two sentence investor summary with source context.

• Pierre Fabre — XOMA’s FY2024 10‑K documents that on February 27, 2024 Kinnate sold exarafenib and related IP to Pierre Fabre for $0.5 million upfront plus $30.5 million in contingent consideration tied to a milestone (XOMA FY2024 10‑K).
• Novartis — FierceBiotech reported that Novartis acquired rights to XOMA’s gevokizumab, reflecting historical asset transfers that reduce XOMA’s direct development obligations (FierceBiotech, FY2017).
• NVS (Novartis ticker) — The same FierceBiotech coverage reiterates Novartis’s purchase of gevokizumab rights, underscoring a legacy commercialization relationship recorded in market press (FierceBiotech, FY2017).
• Ligand Pharmaceuticals (LGND) — Benzinga reported Ligand’s plan to acquire XOMA Royalty for $39.00 per share in cash, a corporate‑level transaction that transfers XOMA’s royalty portfolio to a larger aggregator (Benzinga, 2026).
• Agenus Inc. — A PredictStreet deep‑dive notes XOMA received a $1 million milestone from Agenus tied to Merck’s advancement of MK‑4830 into Phase 2 — an example of milestone receipts that feed XOMA’s near‑term cash flow (PredictStreet / FinancialContent, FY2025).
• Takeda — Investing.com covered an amended collaboration with Takeda that altered the royalty structure for mezagitamab, showing bilateral restructuring of royalty economics (Investing.com, FY2026).
• Takeda (GlobeNewswire disclosure context) — GlobeNewswire’s deal commentary around the Ligand transaction highlights that Takeda’s mezagitamab is one of the late‑stage programs encompassed by the portfolio transfer (GlobeNewswire, 2026).
• Roche — GlobeNewswire lists Roche’s VABYSMO among assets included in the aggregated portfolio acquired by Ligand, indicating XOMA’s historical exposure to Roche‑commercialized revenue (GlobeNewswire, 2026).
• Novartis (2015 press release) — Novartis’s 2015 media release noted an agreement giving Novartis development and commercialization rights to XOMA’s TGF‑beta antibody programs, a prior licensing outcome that monetized R&D IP (Novartis media release, FY2015).
• Day One Biopharmaceuticals — PredictStreet reports XOMA received $9 million following FDA approval of Day One’s OJEMDA, demonstrating how regulatory milestones translate into cash (PredictStreet / FinancialContent, FY2025).
• Medexus Pharmaceuticals — PredictStreet identifies IXINITY® as partnered with Medexus and subject to a mid‑single‑digit royalty rate payable to XOMA, representing steady but modest recurring income when sales occur (PredictStreet / FinancialContent, FY2025).
• MEDXF — The same coverage reiterates Medexus’s role on IXINITY®, confirming the royalty linkage and rate band (PredictStreet / FinancialContent, FY2025).
• Moderna (MRNA) — GlobeNewswire disclosed that XOMA’s Generation Bio acquisition includes a share of proceeds from Generation Bio’s existing license with Moderna, with CVR holders entitled to up to 90% of such payments, creating contingent upside (GlobeNewswire, FY2025).
• Viracta Therapeutics (VIRX) — PredictStreet reports XOMA received $8.1 million from Viracta related to a Priority Review Voucher sale, an example of non‑royalty monetization events that boost cash flow (PredictStreet / FinancialContent, FY2025).
• AVEO Oncology — PredictStreet lists ficlatuzumab as partnered with AVEO with a low‑single‑digit royalty, reflecting small but diversified royalty positions (PredictStreet / FinancialContent, FY2025).
• Takeda (Investing.com duplicate reporting) — A second investing.com item reiterates the amended mezagitamab agreement with Takeda, confirming multiple press touchpoints on the royalty restructuring (Investing.com, FY2026).
• Organon (OGN) — legacy license context — Geneva Biopharma coverage on ObsEva’s sale and subsequent Organon license for ebopiprant notes up to $98 million in milestone potential and $15 million upfront tied to the asset sold into XOMA’s holdings (Geneva Biopharma / GGBA, FY2022).
• Castle Creek Biosciences — PredictStreet notes D‑Fi (FCX‑007), a gene therapy partnered with Castle Creek, as part of XOMA’s royalty exposure in rare disease programs (PredictStreet / FinancialContent, FY2025).
• Daré Bioscience — PredictStreet identifies Ovaprene® as a partnered contraceptive asset; XOMA’s role as royalty collector gives it exposure to commercial adoption if uptake materializes (PredictStreet / FinancialContent, FY2025).
• Zevra Therapeutics (ZVRA) — PredictStreet reports MIPLYFFA (arimoclomol) is partnered with Zevra and subject to a mid‑single‑digit royalty payable to XOMA, fitting the company’s mid‑tail royalty profile (PredictStreet / FinancialContent, FY2025).
• TAK (takeda ticker, FY2025 disclosure) — GlobeNewswire and PredictStreet coverage state Takeda’s royalty and milestone obligations to XOMA related to mezagitamab were reduced with payments reallocated across a basket of nine externalized assets, changing expected cash flows (GlobeNewswire, FY2025).
• TAK (duplicate entry) — An additional filing line reiterates the same Takeda arrangement, underscoring the amendment’s importance to XOMA’s future receipts (GlobeNewswire, FY2025).
• TAK (another item in the same press set) — A further repetition in coverage again records the amended structure for mezagitamab royalties and the basket of assets, confirming consistent public disclosure (GlobeNewswire, FY2025).
• Ligand (GlobeNewswire Mar 12, 2026) — GlobeNewswire announced Ligand’s intention to acquire XOMA Royalty, framing a strategic consolidation of royalty portfolios in the sector (GlobeNewswire, 2026).
• Day One Pharmaceuticals (GlobeNewswire in the Ligand disclosure) — The Ligand announcement calls out Day One’s OJEMDA as one of the commercial assets moving into Ligand’s portfolio, which had previously contributed milestone proceeds to XOMA (GlobeNewswire, 2026).
• Zevra Therapeutics (GlobeNewswire duplicate) — The Ligand transaction commentary lists Zevra programs among the assets being acquired, again linking XOMA’s holdings to later aggregator economics (GlobeNewswire, 2026).
• Gossamer Bio (GOSS) — PredictStreet flags Seralutunib, partnered with Gossamer and Chiesi, where XOMA holds a low to mid‑single‑digit net royalty interest ahead of Phase 3 readouts (PredictStreet / FinancialContent, FY2025).
• Gossamer Bio (duplicate) — A duplicate record reiterates the Gossamer partnership and XOMA’s royalty interest in Seralutunib (PredictStreet / FinancialContent, FY2025).
• AstraZeneca (AZN) — PredictStreet lists rilvegostomig (AZD2936) as a TIGIT/PD‑1 bispecific partnered with AstraZeneca, representing an oncology exposure in XOMA’s portfolio (PredictStreet / FinancialContent, FY2025).
• RZLT (Rezolute) — DrugDiscoveryTrends notes a drug discovered by XOMA and licensed by Rezolute in 2017 that acts on insulin receptor activity, illustrating XOMA’s earlier discovery/licensing role (DrugDiscoveryTrends, FY2026).
• Rezolute (PredictStreet) — PredictStreet commentary records a recent clinical trial setback with Rezolute’s ersodetug but frames XOMA’s diversified royalty strategy and acquisition activity as offsetting single‑asset risk (PredictStreet / FinancialContent, FY2025).
• Talphera (TLPH) — PredictStreet describes DSUVIA® (sufentanil sublingual tablet) as partnered with Talphera and subject to a royalty arrangement with very high DoD‑specific rates (37.5% to 75%), an outlier in XOMA’s royalty mix (PredictStreet / FinancialContent, FY2025).
• Pierre Fabre Laboratories (ad‑hoc commentary) — An ad‑hoc news note explains that with Kinnate’s asset sales, control resides with new asset owners such as Pierre Fabre, making CVR outcomes dependent on external developers (ad‑hoc‑news.de, FY2026).
• OGN (Organon ticker duplicate) — PredictStreet also identifies XACIATO as partnered with Organon and commanding a high single‑digit royalty, reinforcing XOMA’s legacy commercial link with Organon (PredictStreet / FinancialContent, FY2025).
• RHHBF / Roche (ticker alternative) — PredictStreet records VABYSMO’s contribution as roughly a 0.5% royalty to XOMA, an example of a small but stable contribution from a major commercial product (PredictStreet / FinancialContent, FY2025).
• Roche (duplicate) — The same PredictStreet line is repeated under Roche, reiterating the modest royalty percentage from VABYSMO (PredictStreet / FinancialContent, FY2025).

Investment implications and key takeaways

• XOMA is a contract‑driven cash‑flow vehicle: value realization depends on partners hitting regulatory and commercial milestones rather than on XOMA operating products directly.
• Concentration risk exists: a small number of late‑stage and commercial assets drive a disproportionate share of upside, making counterparty execution and deal restructurings (e.g., Takeda amendment) material to valuation.
• Diversified geography and asset mix reduce single‑market risk, but transitions like the Ligand acquisition fundamentally change who ultimately collects future royalties.
• Milestones and one‑time monetizations matter: recent multi‑million dollar payments from Viracta and Day One illustrate how discrete events can move the earnings needle.

For a deeper, sourced breakdown of these relationships and their likely cash‑flow timing, explore XOMA’s transaction histories and press disclosures at https://nullexposure.com/.